Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

by Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M
Published 2020

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

by Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S
Published 2018

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia

by Lambert M, Sanchez P, Bergmans P, Gopal S, Mathews M, Wooller A, Pungor K
Published 2020

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Ho...

by Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Published 2020

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia

by Natalia N. Petrova, Valeria S. Serazetdinova
Published 2020

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparat...

by Li HF, Turkoz I, Zhang F
Published 2015

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

by Emsley R, Kilian S
Published 2018

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability

by Gattaz WF, Saracco-Alvarez R, Daltio CS, Van de Bilt MT, Ortegón JJ, Villaseñor-Bayardo SJ, Louzã M, Elkis H, Soares B, Cabrera Jaramillo P, Lawson F, Díaz-Galvis L
Published 2020

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia

by Emsley R, Hargarter L, Bergmans P, Uglešić B, Sengül AC, Petralia A, Khannanova A, Cherubin P, Schreiner A
Published 2017

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate

by Such P, Olivares JM, Arias L, Troels Berg M, Madera J
Published 2021

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

by Zhao JP, Li LH, Shi JG, Li Y, Xu XF, Li KQ, Zhang LL, Cai SL, Feng Y, Zhuo JM, Liu WH, Lu HF
Published 2017

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia

by Brasso C, Bellino S, Bozzatello P, Montemagni C, Rocca P
Published 2017

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

by Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Published 2019

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia

by Si T, Zhuo J, Feng Y, Lu H, Hong D, Zhang LL
Published 2019

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase II...

by Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Published 2017

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world cli...

by Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C
Published 2019